Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
Rhea-AI Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) reported its Q1 2025 financial results and business updates. The company raised $3.6 million through two registered direct offerings and secured a $12 million equity line of credit. Q1 financial highlights include a net loss of $2.1 million ($0.11 per share), improved from a $4.4 million loss year-over-year, with reduced R&D expenses of $0.6 million and G&A expenses of $1.6 million.
Key developments include positive EMA guidance for ibezapolstat's Phase 3 clinical trial program, aligned with FDA requirements. Two significant studies funded by NIAID demonstrated ibezapolstat's microbiome-restorative potential and favorable gut microbiome impact compared to other antibiotics. The company also secured new patents in Japan and India for DNA polymerase IIIC inhibitors, extending protection until December 2039.
Positive
- None.
Negative
- Continued net losses of $2.1M in Q1 2025
- Multiple equity raises may lead to dilution for existing shareholders
News Market Reaction
On the day this news was published, ACXP declined 3.92%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Highlights of the first quarter ended March 31, 2025, or in some cases shortly thereafter, include:
- In January 2025, the Company announced it had closed a
$2.5 million - Also in January 2025, we announced that we received positive regulatory guidance from the European Medicines Agency (EMA) for the ibezapolstat (IBZ) Phase 3 clinical trial program, which is aligned with FDA on matters of manufacturing, non-clinical and clinical aspects of the Phase 3 program. The EMA guidance also confirmed ibezapolstat's regulatory pathway for a Marketing Authorization Application to be filed by the Company after successful completion of the Phase 3 clinical trials. With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program.
- In February 2025 and in March 2025, we announced new publications in the Journal of Antimicrobial Agents and Chemotherapeutics of two very important non-clinical studies which we believe we can leverage to show further positive differentiation for competitive advantage of IBZ vs all other antibiotics used for the first line therapy of C. difficile infection. And, given our clinical results to date, we're hopeful that this anti-recurrence effect of IBZ could mitigate the need for expensive microbiome therapeutic agents to prevent recurrent CDI.
- In February 2025, we announced positive results from this first study, conducted by Dr. Justin McPherson from the University of
Houston and funded by the National Institute of Allergy and Infectious Diseases (or NIAID). It was an in-silico study that predicted the microbiome-restorative potential of IBZ for treating CDI. Our scientific advisors consider this to be a major finding which provides a mechanistic explanation for IBZ's selectivity in that the predicted bactericidal interaction between IBZ and its target, the DNA pol IIIC enzyme, allows regrowth of gut microbes known to confer health benefits. - In March 2025, we announced the second study, conducted by Dr. Trenton Wolfe, from the University of
Montana , which was funded by the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS), and the Company. This study is the first ever head-to-head comparison of gut microbiome changes associated with IBZ when compared to other anti-CDI antibiotics in a germ-free mouse model. The data showed that changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole (MET)-treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activity. Further, and very importantly, notable differences were observed between the microbiome of IBZ- and the fidaxomicin (FDX)-treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studies.These results establish IBZ's differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDX. - Also in February 2025, the Japanese Patent Office granted a new patent for our DNA polymerase IIIC inhibitors which expires in December 2039, subject to extension. This constitutes a significant building block for our ongoing development of ACX-375C, our pre-clinical antibiotic candidate targeting the treatment of MRSA, VRE and Anthrax infections.
- In March 2025, we announced the closing of a registered direct offering and concurrent private placement, raising gross proceeds of
$1.1 million - In April 2025, the Indian Patent Office granted a new patent for our DNA polymerase IIIC inhibitors which expires in December 2039, subject to extension. This constitutes another significant building block for our ongoing development of ACX-375.
- In May 2025, we closed an equity line of credit with Lincoln Park Capital for up to
$12 million
First Quarter 2025 Financial Results
Cash Position:
The Company ended the quarter with cash totaling
R&D Expenses:
Research and development expenses for the three months ended March 31, 2025 were
G&A Expenses:
General and administrative expenses for the three months ended March 31, 2025 were
Net Income/Loss:
The Company reported a net loss of
The Company had 22,397,511 shares outstanding as of March 31, 2025.
Conference Call
As previously announced, David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
Date: | Tuesday, May 13, 2025 |
Time: | 8:00 a.m. ET |
Toll free ( | 1-877-790-1503; Conference ID: 13753625 |
International: | Click here for participant international Toll-Free access numbers |
About Ibezapolstat
Ibezapolstat is the Company's lead antibiotic candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillinresistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & Chief Executive Officer
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM BALANCE SHEETS | ||||||
March 31, | December 31, | |||||
2025 | 2024 | |||||
ASSETS | ||||||
CURRENT ASSETS | ||||||
Cash | $ | 4,643,887 | $ | 3,706,713 | ||
Other Receivable | — | 51,127 | ||||
Prepaid Expenses | 161,574 | 100,123 | ||||
TOTAL ASSETS | $ | 4,805,461 | $ | 3,857,963 | ||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES | ||||||
Accounts Payable and Accrued Expenses | $ | 2,494,062 | $ | 3,242,842 | ||
TOTAL CURRENT LIABILITIES | 2,494,062 | 3,242,842 | ||||
TOTAL LIABILITIES | 2,494,062 | 3,242,842 | ||||
COMMITMENTS AND CONTINGENCIES | ||||||
SHAREHOLDERS' EQUITY | ||||||
Common Stock; 22,397,511 and 17,030,686 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 22,398 | 17,031 | ||||
Additional Paid-In Capital | 71,760,150 | 67,920,046 | ||||
Accumulated Deficit | (69,471,149) | (67,321,956) | ||||
TOTAL SHAREHOLDERS' EQUITY | 2,311,399 | 615,121 | ||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 4,805,461 | $ | 3,857,963 | ||
ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM STATEMENTS OF OPERATIONS | ||||||
Three Months Ended | ||||||
March 31, | ||||||
2025 | 2024 | |||||
(unaudited) | (unaudited) | |||||
OPERATING EXPENSES | ||||||
Research and Development | $ | 598,798 | $ | 1,555,011 | ||
General and Administrative | 1,550,395 | 2,822,878 | ||||
TOTAL OPERATING EXPENSES | 2,149,193 | 4,377,889 | ||||
NET LOSS | $ | (2,149,193) | $ | (4,377,889) | ||
LOSS PER SHARE | ||||||
Basic and diluted net loss per common share | $ | (0.11) | $ | (0.28) | ||
Weighted average common shares outstanding, basic and diluted | 20,038,648 | 15,472,507 | ||||
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-reports-first-quarter-results-and-provides-business-update-302452432.html
SOURCE Acurx Pharmaceuticals, Inc.
FAQ
What were ACXP's key financial results for Q1 2025?
How much funding did Acurx Pharmaceuticals raise in Q1 2025?
What progress did ACXP make with ibezapolstat in Q1 2025?
What new patents did Acurx receive in early 2025?
How did ACXP's Q1 2025 performance compare to Q1 2024?
